NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 1865-1869

  Papadopoulou, Maria V ^a   Bloomer, William D ^a   Hollingshead, Melinda G ^b  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Human gliomas; Hypoxia; NLCQ 1; Radiation

Indexed keywords

4 [3 (2 NITRO 1 IMIDAZOLYL)PROPYLAMINO] 7 CHLOROQUINOLINE; ANTINEOPLASTIC AGENT; NCLQ 1; NSC 709257; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GLIOMA; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; TOXICITY; TREATMENT OUTCOME; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GLIOMA; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; QUINOLINES; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 21344456979     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kayama T, Yoshimoto T, Fujimoto S. and Sakurai Y: Intratumoral oxygen pressure in malignant brain tumors. J Neurosurg 74: 55-59, 1991
2. Valk PE, Mathis CA, Prados MD, Gilbert JC and Budinger TF: Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33: 2133-2137, 1992.
3. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29: 427-31, 1994.
4. Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A and Aleksandrovic J: Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high grade astrocytomas: a phase II study. Radiother Oncol 51: 27-33, 1999.
5. Brown JM: The hypoxic cell: a target for selective cancer therapy - Eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59: 5863-5870, 1999.
6. Brown JM: Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6(4): 157-162, 2000.
7. Harris AL: Hypoxia - a key regulatory factor in tumor growth. Nature Rev Cancer (Phila.) 2: 3338-47, 2002.
8. Stratford IJ and Workman P: Bioreductive drugs into the next millennium. Anticancer Drug Design 13: 519-528, 1998.
9. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W, Meehan L, McKeon A, Devin J, von Roemeling R and Viallet J: Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 16: 3524-3527, 1998.
10. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J and Treat J: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J Clin Oncol 18: 1351-1359, 2000.
11. Aquino VM, Weitman SD, Winick NJ, Blaney S, Furman WL, Kepner JL, Bonate P, Krailo M, Qu W and Bernstein M: Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J Clin Oncol 22: 1413-1419, 2004.
12. Papadopoulou MV, Ji M, Rao MK and Bloomer WD: 4-[3-(2-Nitro-1-imidazolyl) -propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12: 185-192, 2000.
13. Papadopoulou MV and Bloomer WD: NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug [Review]. Clin Cancer Res 9: 5714-5720, 2003.
14. Papadopoulou MV and Bloomer WD: Exploiting hypoxia in solid tumors with DNA-targeted bioreductive drugs [Review]. Drugs Future 29(8): 807-819, 2004.
15. Reid JM, Squillace DP and Ames MM: Single dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 Mice. Cancer Chem Pharmacol 51: 483-487, 2003.
16. Plowman J, Dykes DJ, Hollingshead M, Simpson-Herren L and Alley MC: Human tumor xenograft models in NCI drug development. In: Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (Teicher B, ed). Totowa, NJ, Humana Press Inc, pp. 101-125, 1997.
17. Dykes DJ, Abbott BJ, Mayo JG, Harrison SD, Laster WR, Simpson-Herren L and Griswold DP: Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol, Karger AG, Basel, 1992, Vol 42, pp 1-22.
18. Papadopoulou MV, Ji M, Rao MK and Bloomer WD: 4-[3-(2-Nitro-1-imidazolyl) -propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosensitizer in vitro and in vivo. Comparison with tirapazamine. Oncol Res 12: 325-333, 2000.
19. Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh J, Papadopoulou M, Bloomer WD and Goldenberg DM: Optimizing the use of combined radio-immunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 94: 564-571, 2001.
20. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt S, Shoemaker RH and Melillo G: Schedule-dependent inhibition of HIF-1 protein accumulation, angiogenesis and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64(19): 6845-6848, 2004.
21. Yuan X, Tabassi K and Williams JA: Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma. Radiat Oncol Invest 7: 218-230, 1999.
22. Dorie MJ and Brown JM: Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39: 361-366, 1997.
23. Brown JM and Giaccia AJ: Tumor hypoxia: the picture has changed in the 1990s. Int J Radiat Biol 65: 95-102, 1994.
24. Cardinale RM, Dillehay LE, Williams JA, Tabassi K, Brem H and Lee D-J: Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice. Radiat Oncol Invest 6: 63-70, 1998.